Zero Human Deaths from Dog-mediated Rabies by 2030: Perspectives from Quantitative and Mathematical Modelling
Overview
Public Health
Affiliations
Dog-mediated rabies continues to kill tens of thousands of people every year in low- and middle-income countries despite being an entirely vaccine-preventable disease. WHO and partners have launched a global campaign to reach zero human deaths from dog-mediated rabies by 2030. The primary tools for reaching this target are mass dog vaccination to interrupt transmission in domestic dog populations that maintain infection, appropriate post-exposure prophylaxis (PEP) for rabies-exposed persons to prevent the fatal onset of disease, together with education to support their effective uptake. Models have been developed to assess the feasibility, impact and cost-effectiveness of these measures. From these models, we argue that the 2030 target of zero human rabies deaths is achievable, but will require concerted effort, engagement and investment. A proposed Gavi investment in human rabies vaccines has potential to drive progress towards the 2030 target; however, concomitant investment is needed to scale up mass dog vaccination or this target will be missed. Predicted economic benefits of mass dog vaccination vary according to national PEP provisioning and healthcare access. Integrated Bite Case Management can enhance surveillance and rationalize PEP use, but needs adapting to and integrating within local health systems and international reporting systems to improve PEP accountability, monitor impacts and support verification of disease freedom. Modelling approaches need refining to project realistic and geographically specific timelines for achieving targets. Model iterations informed by data on the implementation of interventions can be used to evaluate progress and guide future strategies. Critically such models are needed to advocate for investment, since the greatest risk to the 'Zero by 30' strategy is the limited long-term cross-sectoral or targeted financing to support countries to deliver and sustain mass dog vaccination.
Burden of human rabies disease: its potential prevention by means of Rabipur vaccine.
Amicizia D, Lai P, Massaro E, Panatto D J Prev Med Hyg. 2025; 65(3):E356-E370.
PMID: 39758769 PMC: 11698110. DOI: 10.15167/2421-4248/jpmh2024.65.3.3404.
Study of fractional order rabies transmission model via Atangana-Baleanu derivative.
Zainab M, Boulaaras S, Aslam A, Shafiq S, Hussain T, Ozair M Sci Rep. 2024; 14(1):25875.
PMID: 39468249 PMC: 11519564. DOI: 10.1038/s41598-024-77282-0.
Machine learning to improve the understanding of rabies epidemiology in low surveillance settings.
Keshavamurthy R, Boutelle C, Nakazawa Y, Joseph H, Joseph D, Dilius P Sci Rep. 2024; 14(1):25851.
PMID: 39468157 PMC: 11519585. DOI: 10.1038/s41598-024-76089-3.
Benefit-cost analysis of coordinated strategies for control of rabies in Africa.
Bucher A, Dimov A, Fink G, Chitnis N, Bonfoh B, Zinsstag J Nat Commun. 2023; 14(1):5370.
PMID: 37679314 PMC: 10484917. DOI: 10.1038/s41467-023-41110-2.
Integrating full and partial genome sequences to decipher the global spread of canine rabies virus.
Holtz A, Baele G, Bourhy H, Zhukova A Nat Commun. 2023; 14(1):4247.
PMID: 37460566 PMC: 10352342. DOI: 10.1038/s41467-023-39847-x.